Recro Pharma, Inc.
(NASDAQ : REPH)

( )
REPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.61%284.001.4%$846.81m
AMGNAmgen, Inc.
0.11%221.101.3%$516.31m
CELGCelgene Corp.
-0.03%109.991.3%$466.64m
GILDGilead Sciences, Inc.
-0.29%64.881.0%$399.18m
VRTXVertex Pharmaceuticals, Inc.
2.34%209.801.9%$313.89m
ILMNIllumina, Inc.
-1.10%302.613.5%$307.88m
REGNRegeneron Pharmaceuticals, Inc.
1.92%344.872.6%$267.68m
EXASEXACT Sciences Corp.
3.55%82.0524.0%$209.78m
ALXNAlexion Pharmaceuticals, Inc.
2.34%108.372.0%$179.80m
SGENSeattle Genetics, Inc.
1.29%114.756.1%$136.96m
BMRNBioMarin Pharmaceutical, Inc.
-0.71%75.044.3%$123.64m
SRPTSarepta Therapeutics, Inc.
0.05%97.4614.6%$115.38m
AAgilent Technologies, Inc.
1.95%78.261.6%$101.36m
NBIXNeurocrine Biosciences, Inc.
2.89%113.055.0%$90.40m
BGNEBeiGene Ltd.
0.94%198.252.1%$88.64m

Company Profile

Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.